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E-call Logging System at DPIC:
 
The Drug and Poison Information Centre (DPIC) at 
the Aga Khan University Hospital (AKUH) operates 
round the clock and provides up-to-date, unbiased, 
evidence-based information in a timely manner. 
The Centre entertains 2300 – 2500 drug and poison 
related queries per month from health care profes-
sionals and the general public. The manual process 
of documentation at DPIC has been computerized 
following the in-house development of e-call log-
ging software by our IT team. To our knowledge, 
this innovation is one of its kind in this region. The 
aim is to have a database of routine medication re-
lated information and toxicology management re-
lated queries all at one place. Other benefits of the 
new software include standardization of the pro-
cess, quick retrieval of the documented informa-
tion, a tool for training and development and re-
search; last but not the least, it will also minimise 
the cost of paper, a small step towards a paperless 
environment.
CPOE Featured with more Robust Allergies 
Information:
Drug allergies are common in clinical practice; 
cross allergy is 
the presence 
of allergy to a 
drug and other 
relevant similar 
drugs. The imple-
mentation of the 
C o m p u te r i ze d 
Physician Order Entry (CPOE) System at AKUH has 
resulted in curtailing many types of medication er-
rors. System modifications to add on to the clinical
decision supports are an on-going feature of CPOE. 
Another innovation is the linkage of drug allergies 
with the possible cross allergenic drugs of the same 
or related drug class.  The system will identify if a 
cross allergy is possible with a drug when data on 
an allergy is updated in the CPOE system. This will 
reduce the chances of accidentally prescribing a 
cross-allergy drug to an allergic patient.
Initiation of Point of Care Clinical Pharmacy 
Services in Paeds Oncology:
Inception of Point Care Pharmacy (PCP) services is 
already contributing to the optimal medication us-
age and fostering the patient safety in various criti-
cal care and selected high risk wards of the hospi-
tal. The recent addition to the PCP services is Paeds 
Oncology unit.  The newly designated pharmacist in 
Paeds Oncology is engaged in reviewing the chemo-
therapy protocols, standardising the IV infusions, 
hepatic and renal dose adjustments, cost curtail-
ment, rational use of antibiotics and resolving other 
drug related problems. 
The physician-pharmacist, nurse-pharmacist and 
patient-pharmacist interaction has also increased 
to facilitate proper patient care.
Pharmacy News
Allergies Information Updated in CPOE
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Sulfa Allergy: Myths and Realities
How will you respond to your patient if he/she asks? 
I have a sulfa allergy. How would I know if a medicine contains sulfa? Should I simply avoid those drugs that 
have the prefix ‘sul’ or ‘sulfa’?”
Answering such queries is never an easy task for health care providers such as doctors, nurses or pharma-
cists. There is a need of in-depth knowledge of the chemical groups, their interrelation and patient dynamics. 
Avoiding only medications with the prefix ‘sul’ or even ‘sulfa’ is not a good rule of thumb if one has a docu-
mented sulf allergy.
A typical worry is that a person who is allergic to sulfa drugs may have problems with substances that contain 
sulfur. No one is allergic to sulfur itself and sulfur is not present as an isolated element in the body, but in 
combination with other elements and, most often, in complex molecules. The primary placement of sulfur 
in the human body is in the sulfur containing amino acids: methionine, cysteine, homocysteine and taurine. 
Sulfa drugs are more appropriately labelled sulfonamides and are derivatives of para-amino benzoic acid. The 
table below lists common medications that contain a sulfonamide component. 
Sulfonamide drug classes/individual drugs that may cause allergic reactions
Sulfonamide 
Antibiotics
Thiazide Diuretics Loop 
Diuretics
Sulfonylureas Carbonic Anhy-
drase Inhibitors
Sulfabenzamide
Sulfacetamide
Sulfadiazine
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulfathiazole
Sulfisoxazole
Chlorothiazide
Chlorthalidone
Hydrochlorothiazide
Indapamide
Methyclothiazide
Metolazone
Furosemide Chlorpropamide
Tolbutamide
Tolazamide
Glipizide
Glibenclamide
Glimepiride
Acetazolamide
Mechanism of Allergic Reaction:
Sulfa drugs are usually not allergenic by themselves, but when a sulfonamide molecule is metabolised in the 
body it is capable of attaching to proteins, thus forming a larger molecule that could serve as an allergen. 
Thus, the allergy is not due to the original drug, but the drug-protein 
complex. It is estimated that a skin rash occurs in about 3.5 percent 
of hospitalised patients receiving sulfonamides, but people with HIV 
infection seem to have a considerably higher sensitivity to them.
There are also a number of other medications related to sulfona-
mides. Although the medications noted below are probably safe to be taken if there is a 
known sulfa allergy, but one should carefully review the severity of allergy and the risk versus benefit ratio of 
using these drugs in such patients. Examples include, but are not limited to: 
• Some nonsteroidal anti-inflammatory drugs, such as Celecoxib 
• Anti Migraine medication, Sumatriptan 
Sulfa Drugs Allergy
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Allergy to Sulfites:
What are sulfites?  Sulfites (or sulfiting agents) refer to a group of simple chemicals that include sulphur di-
oxide and sulfite salts. They are produced naturally in some foods, mainly those undergoing fermentation. 
Sulfites are metabolised to sulphur dioxide under certain conditions that depend on concentration, heat, 
and pH.
Sulfite Vs Sulfa Drug Allergy: A sulfite reaction is different from a sulfa drug allergy because sulfites and sul-
fonamides are entirely different chemicals and have unrelated mechanisms of reaction. A person sensitive to 
sulfites is no more likely to be allergic to sulfonamides than any other individual and vice versa. 
Sulfites in Food Products: Some sulfiting agents are FDA approved preservatives that are added to food and 
pharmaceuticals. The more common sulfiting agents are sodium sulfite (Na2SO3), sodium bisulfite (NaHSO3), 
and sodium metabisulfite (Na2S2O3).  
Because of concerns about sulfite sensitivity, there is a requirement imposed by the FDA to label packaged 
foods as having sulfites if they contain as little as 10 parts per million (ppm). Generally, foods with less than 
100 ppm of sulfites will not affect sensitive asthmatics, so there is a tenfold safety margin.
However, the FDA has banned adding sulfites to fresh fruits and vegetables offered in restaurants and other 
public venues due to concerns that were raised. Juices squeezed from lemons and limes will not have sulfites, 
but bottled or dehydrated juice may contain sulfites.
Foods that may contain sulfites
Dried soup mixes
Vegetable juices
Baked goods
Canned or dried fish
Dried fruit
Relishes 
Maraschino cherries
Dehydrated vegetables
Shredded coconut 
Sauerkraut
Dried noodle meals
Olives
Pickles
Shrimp, lobster, scallops
Lemon and lime juice
Jams and jellies
Grape juice
Wine
Molasses
Gravies
Potatoes
Terbutaline
Serious heart problems in infants and death of the mother may occur in 
pregnancy. Also, oral terbutaline has not been shown to be effective to 
prevent or treat preterm labour.
Rosiglitazone It may increase the risk of a heart attack
Topiramate Risk for development of cleft lip and/or cleft palate in newborns
Proton Pump Inhibitor (PPIs) Low magnesium levels can be associated with long-term use
Antipsychotic drugs 
There is a potential risk of abnormal muscle movements (extrapyramidal 
signs or EPS) and withdrawal symptoms in newborns whose mothers were 
treated with these drugs during the third trimester of pregnancy.
Angiotension Receptor 
Blockers (ARBs)
A recently published meta-analysis suggested that the use of ARBs may 
be associated with a small increased risk of cancer. However, FDA has not 
concluded that ARBs increase the risk of cancer. The Agency is reviewing 
information related to this safety concern and will update when additional 
information is available. FDA believes the benefits of ARBs continue to out-
weigh their potential risks.
Proton Pump Inhibitor (PPIs)
FDA informs health care professionals and patients that they should be 
aware of the possible increased risk of fractures of the hip, wrist, and 
spine with the use of proton pump inhibitors. Prescribers should weigh the 
known benefits against the potential risks when prescribing these drugs.
Drug Safety Updates (2010 - 2011)
Source: www.fda.gov 
